Details : Radotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2018
Lead Product(s) : Radotinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Details : Radotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2012
Lead Product(s) : Radotinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Radotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2012
Reset All
